AstraZeneca Cancer Drug Review Delayed
AstraZeneca's breast cancer treatment application faces extended review by FDA, potentially impacting approval timeline. This may affect AstraZeneca's stock performance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.